International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 900-905 doi: 10.5281/zenodo.16918281
Original Article
A study on Prevalences of Shellfish Consumption and its Allergy (Type I Hypersensitivity Reaction) and its Clinical Medical Management in a Tertiary Care Hospital of Haldia, West Bengal: A cross-sectional observational study
 ,
 ,
 ,
Published
Aug. 21, 2025
Abstract

Background: Shellfish is a common dietary component in coastal Bengal. However, shellfish allergy, a form of IgE-mediated Type I hypersensitivity reaction, is increasingly recognized as a health concern. This study investigates the prevalence of shellfish consumption, prevalence of shellfish allergy, associated risk factors, and clinical management among patients in a tertiary care hospital in Haldia, West Bengal. Methods: A cross-sectional observational study was conducted on 36 patients attending the tertiary care hospital. Data regarding shellfish consumption, allergic reactions, demographic profile, risk factors, and management were collected using structured questionnaires and medical records. Statistical analysis included calculation of prevalence, odds ratio (OR), and association between risk factors and shellfish allergy. Results: The prevalence of shellfish consumption was 77.7% (28/36). The prevalence of shellfish allergy among consumers was 21.4% (6/28). Major clinical manifestations included urticaria (50%), angioedema (33.3%), and anaphylaxis (16.7%). Significant risk factors included family history of allergy (OR = 3.2), asthma (OR = 2.8), and atopic dermatitis (OR = 2.5). Management primarily consisted of antihistamines (100%), corticosteroids (66.7%), and adrenaline for severe cases (16.7%). Conclusion: Shellfish allergy is an important health concern in coastal West Bengal. Early recognition of risk factors, public awareness, and prompt clinical management are essential to reduce morbidity.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
215 Views
198 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved